Lupin, through its subsidiary Lupin Atlantis Holdings SA, has entered into a licensing and supply agreement with Galenicum Health, S.L.U. for finished formulations of injectable Semaglutide. The agreement grants Lupin rights for commercialization across 23 countries, including Canada, Europe, Southeast Asia, and Latin America. Galenicum will oversee development and manufacturing. This partnership expands Lupin’s presence in the diabetes and obesity care markets.
Semaglutide Licensing Agreement
Lupin Limited announced on January 21, 2026, a licensing and supply agreement with Galenicum Health, S.L.U. (Galenicum) for finished formulations of injectable Semaglutide, a GLP-1 receptor agonist. The agreement was made through Lupin’s subsidiary, Lupin Atlantis Holdings SA (LAHSA).
Agreement Details
According to the agreement, Galenicum will manage the development, manufacturing, and supply of Semaglutide. Lupin will handle regulatory submissions, approvals, and the commercial distribution of Semaglutide in 23 countries. These countries include Canada, Europe, Southeast Asia, and Latin America.
Strategic Significance
Lupin’s management views this partnership with Galenicum as a key strategic step to strengthen its Semaglutide portfolio. The company aims to expand its presence in diabetes and obesity care beyond India. Fabrice Egros, President, Corporate Development, Lupin stated that this collaboration allows Lupin to capitalize on growth opportunities in the expanding GLP-1 market and to scale access to cost-effective medicines.
Galenicum’s Perspective
According to Joaquim Domingo, co-founder of Galenicum, this partnership is a cornerstone of their strategy to scale high-impact volumes of Semaglutide globally. Galenicum has invested heavily in its GLP-1 development pipeline to meet the rising demand for these therapies.
Source: BSE
